ClinicalTrials.gg
RecruitingNCT06841159iPULSAR-CRCUpdated Oct 19, 2026

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1,Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

A Phase 2 interventional study of Ultra-fractionated radiation therapy and Sintilimab in Microsatellite Stable Metastatic Colorectal Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.
Updated Oct 19, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing sintilimab in Colorectal Neoplasms — 15 open to participants now, 18 under way, 3 of them phase 3. sintilimab · Colorectal Neoplasms.

Planned enrollment
5th of 26
116 · median 42
Started
2024
with 4 others
Phase 2
19 of 26
10 open now
Primary completion
2029-09
later than 17 of 17 live
Registered
17th of 26
by date
Lead sponsor
3 of 26
Fudan University

Among the 26 studies testing sintilimab in Colorectal Neoplasms, this one is the 5th largest by planned enrollment, is one of 5 that started in 2024, is one of 19 in phase 2, reaches primary completion later than 17 of the 17 other live ones, and was the 17th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 26 studies testing sintilimab in Colorectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing sintilimab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

To improve the survival in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) by loco-regional therapy with personalized ultra-fractionated radiation plus immunotherpy.

Read the detailed description

IPULSAR-CRC is a prospective, single-arm, two-cohort, investigator-initiated phase II trial to investigate the efficacy and safety of Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) plus sintilimab in combination with standard systemic therapy in paitents with microsatellite stable metastatic colorectal cancer (MSS mCRC). Eligible patients will be assigned to two cohorts according to previous treatment: a first-line cohort A and a second-line cohort B. Patients in both arms will receive PULSAR, administered in 5 fractions of 6-10 Gy each (30-100 Gy total) at 3 week intervals. Sintilimab will be administered 200mg every 3 weeks and schedule to the next day of every pulses of radiation. Standard systemic therapy will be administered based on previous chemotherapy and adverse reactions to chemotherapy agents and at the discretion of the oncologist.The survival benefits, response rates, and adverse effects will be analyzed.

03

Conditions studied

  • Microsatellite Stable Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is 18-75 years old at the time of signing the form.
  • performance status 0-1.
  • Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum.
  • Distant lesions are no more than 10 and all sites of disease can be safely treated based on a pre-plan.
  • At least one evaluable metastatic lesion for radiotherapy and evaluation according to 1.1.
  • No prior radiotherapy within 6 month.
  • Previous system therapy. Patients Group Cohort A: participants who have not previously been treated with chemotherapy. Cohort B: Patients with disease progression after first-line chemotherapy or stopped first-line therapy due to unacceptable toxic effects .
  • Has an investigator determined of at least 24 weeks.
  • Demonstrate adequate organ function (bone marrow, liver, kidney and clotting function) within 7 days before the first administration without using blood products or hematopoietic stimulating factors.
  • Non pregnant or lactating patients. Effective methods should be used during the study and within 6 months of the last administration.
  • Fully informed and willing to provide written informed consent for the trial.

Exclusion criteria

Exclusion Criteria:

  • History of therapy.
  • Neutrophil\< 1.5×109/L, \< 100×109/L (PLT\< 80×109/L in patients with liver ), or \< 90 g/L.
  • > 1.5 , or TBIL > 2.5 ULN in patients with liver metastasis. or ALT > 2.5 ULN, or ALT and/or AST > 5 ULN in patients with liver metastasis.
  • Cr > 1.5 ULN, or \< 50 mL/min (calculated according to Cockcroft Gault formula).
  • > 1.5 ULN, PT > 1.5 ULN (subject to the normal value of the clinical trial research center).
  • Serious electrolyte abnormalities.
  • Urinary protein ≥ 2+, or 24-h urine protein ≥1.0 g/24 h.
  • Uncontrolled hypertension: SBP >140 mmHg or DBP > 90 mmHg.
  • A history of arterial thrombosis or deep vein thrombosis within 6 months; a history of bleeding or evidence of bleeding tendency within 2 months.
  • A history of heart disease within 6 months.
  • Uncontrolled malignant pleural effusion, ascites, or pericardial effusion.
  • The presence of a clinically detectable second primary , or history of other malignancies within 5 years.
  • A history of liver disease including, but not limited to, infection or HBV DNA positive (≥1×104/mL), infection or HCV DNA positive (≥1×103/mL),and liver cirrhosis.
  • Pregnant or lactating women or women who may be pregnant have a positive pregnancy test before the first medication, or the female participants themselves and their partners who were unwilling to implement strict during the study period.
  • The investigator considers that the subject is not suitable to participate in this clinical study due to any clinical or laboratory abnormalities or compliance problems.
  • Serious mental abnormalities.
  • The diameter of is greater than 3 cm or the total volume is greater than 30 cc.
  • Clinical or radiological evidence of spinal cord compression, or tumors within 3 mm of the spinal cord on MRI.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    a first-line cohort A and a second-line cohort B

    Personalized Ultra-fractionated Stereotactic Radiotherapy (PULSAR) plus sintilimab and standard systemic therapy.

    Radiation: Ultra-fractionated radiation therapy · Drug: Sintilimab · Drug: Standard systemic therapy

Interventions

  • RadiationUltra-fractionated radiation therapy

    Radiation therapy will be delivered every 3 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of sintilimab.

  • Sintilimab will be given at 200 mg q3w every 3 weeks and schedule to the next day of every pulses of radiation.

  • DrugStandard systemic therapy

    First-line standard systemic therapies in cohort A include: FOLFOX/FOLIRI/XELOX+ bevacizumab, FOLFOX/FOLIRI/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only). Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    time from the date of start treatment until disease progression or censored at last follow-up or death.

    Time frame: up to 2 years

Secondary outcomes

  1. Overall Survival (OS)

    from the date of start treatment until the date of death from any cause or censored at last follow-up.

    Time frame: up to 3 year

  2. Objective response rate (ORR)

    the proportion of patients with the best response of confirmed complete or partial response according to iRECIST in all metastatic lesions.

    Time frame: up to 1 year

  3. Disease control rate (DCR)

    the proportion of patients with disease control in all metastatic lesions. Disease control is defined as CR, PR, or stable disease (SD) per iRECIST after treatment.

    Time frame: up to 1 year

  4. Duration of response (DOR)

    time from the first documented objective response to disease progression in patients with confirmed response.

    Time frame: up to 2 years

  5. Adverse events

    The percentage of patients with treatment-related acute toxicities as assessed by NCI CTCAE v5.0, from treatment initiation until 90 days upon completion of immunotherapy.

    Time frame: up to 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2029, 60 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 60 months is close to that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Mar 2024 → Sep 2024, primary completion Mar 2026 → Sep 2029 and completion Mar 2028 → Sep 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2024
First posted
Feb 24, 2025
StartActual
Sep 30, 2024was Mar 2024
Primary completionEst.
Sep 30, 2029was Mar 2026
CompletionEst.
Sep 30, 2030was Mar 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 1, 2024→Sep 30, 2024
Oct 19, 2026
Primary completion
Mar 1, 2026→Sep 30, 2029
Oct 19, 2026
Study completion
Mar 1, 2028→Sep 30, 2030
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Start date Mar 1, 2024→Sep 30, 2024
    Primary completion Mar 1, 2026→Sep 30, 2029
    Study completion Mar 1, 2028→Sep 30, 2030
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06841159
Lead sponsor
Fudan University
Responsible party
Zhen Zhang (MD, PhD, Fudan University) — Principal investigator
First posted
Feb 24, 2025
Start date
Sep 30, 2024
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Zhen Zhang, MD,PhD
Contact
zhen_zhang@fudan.edu.cn
86-0204256577200

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion